骨质疏松症风险一分钟测试在评价绝经后女性超声骨 密度变化中的作用

目的探讨骨质疏松症风险一分钟测试在评价绝经后女性跟骨超声骨密度变化中的作用。方法对273名门诊就诊的绝经后妇女进行骨质疏松风险一分钟测试,并采用韩国SONOST 3000超声波骨密度检测仪测定受试者右跟骨SOS值、BUA值、BQI值及T值,按问卷测试结果对各组进行统计学分析。结果问卷测试阳性组受试者年龄较高(P0.01)、身高较低(P0.05)、体重较轻(P0.01),跟骨定量超声各参数及骨密度T值均显著低于阴性组(P0.01)。随年龄或OSTA风险增加,测试结果阳性率升高(P0.05),骨密度T值显著降低(P0.05)。在所有测试问题中,问题2和问题4阳性回答受试者的BQI值及骨密度T值均明显低于阴性回答受试者,差异具有统计学意义(P0.05)。结论骨质疏松症风险一分钟测试可以简便、有效地反映骨质疏松骨密度改变,特别对于测试问题2或问题4阳性的绝经后女性应引起高度警惕,建议及早诊治。     

2型糖尿病对老年绝经后女性骨质疏松性骨折风险的影响

目的探讨2型糖尿病(type 2 diabetes mellitus,T2DM)对老年绝经后女性骨质疏松性骨折风险的影响,为预防骨质疏松性骨折及制订相关干预措施提供依据。方法 180例绝经后T2DM女性作为糖尿病组,180例健康绝经后女性作为对照组,比较两组的基本资料、T2DM史、骨折史,骨密度(BMD)、骨转化指标,并比较组间资料和指标差异,生存分析T2DM对骨质疏松性骨折风险的影响。结果糖尿病组腰椎BMD、股骨颈BMD、I型前胶原氨基端肽(procollagen 1 N-terminal peptide,P1NP)显著低于对照组(P0.05),β-Ι型胶原羧基端肽(beta C-terminal telopeptide,β-CTX)组间无显著差异(P0.05);糖尿病组有骨折史人数(率)为25(13.9%),高于对照组12(7.8%)(P0.05),骨折部位分布组间无显著差异(P0.05);生存分析显示T2DM无骨折生存率低于对照组(P0.05)。结论 T2DM可降低老年绝经后女性的骨密度,影响骨转化,可能增加骨质疏松性骨折的风险,应采取措施积极加强预防和干预。     

血清羧化不全骨钙素对绝经后女性骨质疏松症诊疗意义的探讨

目的检测绝经后女性血清羧化不全骨钙素(ucOC)的水平,并探讨其影响因素及其对绝经后女性骨质疏松症诊疗的意义。方法选择南京医科大学附属南京医院2015年07月至2016年12月在骨科门诊就诊的绝经后女性患者108例,依据骨密度检查将这些患者分为骨质疏松组与非骨质疏松组;记录其年龄、身高、体重、体重指数(BMI)、绝经年龄、骨密度(BMD)等相关资料;抽取外周血测定碱性磷酸酶(ALP)、血钙、血磷、羧化不全骨钙素(ucOC)的水平,并对上述资料进行相关的统计学分析。结果绝经后女性骨质疏松组患者的血清ucOC水平与非骨质疏松组相比差异有统计学意义(P0.05);血清ucOC水平是骨质疏松症的影响因素(OR=2.806,P0.05)。(2)血清ucOC水平与腰椎骨密度呈负相关(r=-0.395,P0.05),但与髋关节骨密度无显著相关性(r=-0.248,P0.05)。结论血清ucOC水平的变化与绝经后女性骨质疏松症的发生关系密切,血清高ucOC水平是绝经后女性骨质疏松症发生的危险因素;推断血清ucOC水平对于绝经后女性骨质疏松症早期的预测和筛查具有参考意义     

绝经后不同骨关节退行性疾病与骨质疏松程度的相关性研究

目的探讨绝经后女性不同骨关节退行性疾病的临床特点及与骨密度的关系,为防治绝经后骨关节退行性疾病提供依据。方法选取2013年9月至2016年3月在我院收治的959例绝经后女性患者,取腰椎和股骨颈处的最大的骨密度值及T值作为研究对象,按不同骨关节退行性疾病分为脆性骨折组、腰椎退行性病变组、膝骨关节炎组及无明显骨关节疾病对照组。采用SPSS 19.0软件进行统计学分析。结果 (1)各组间腰椎BMD值及T值的差异具有统计学意义(P0.05),其中腰椎退行性病变组患者的腰椎骨密度值和T值均比其他3组明显减低(P0.05),膝骨关节炎组骨密度值和T值均高于其他3组(P0.05);(2)各组间股骨颈BMD值及T值的差异具有统计学意义(P0.05),其中脆性骨折组患者的股骨颈骨密度值和T值均比其他3组明显减低(P0.05),膝骨关节炎组骨密度值和T值均高于其他3组(P0.05)。结论在绝经后女性患者中,脆性骨折与骨质疏松的关系最为密切,而其他骨关节疾病也在不同程度上与骨质疏松程度存在显著相关性,在治疗骨关节疾病的同时也要重视骨质疏松症的防治。     

绝经后女性促甲状腺激素水平与骨质疏松性骨折的相关性研究

目的探讨绝经后女性血清促甲状腺激素水平与骨质疏松性骨折的相关性。方法 2011年5月至2011年10月期间对贵阳市云岩区4 073名40岁及以上居民开展问卷调查、体格检查、促甲状腺激素(thyroid stimulating hormone,TSH)检验及跟骨超声骨密度测定等。根据基线TSH水平,将调查对象分为3组,分别是TSH降低组(TSH0.55 mIU/L,71人)、TSH正常组(0.55 mIU/L≤TSH≤4.78 mIU/L,3 113人)、TSH升高组(TSH4.78 mIU/L,889人),比较各组基线特征。随访3年后,根据随访期内是否发生骨折分析不同TSH水平与骨质疏松性骨折的相关性。结果 TSH降低组、TSH正常组、TSH升高组中新发骨质疏松性骨折的人数分别为8例、51例、148例,发病率分别为11.3%、4.8%、5.7%,TSH降低组骨折发病率高于TSH正常组,差异具有统计学意义(P=0.012)。TSH升高组较正常组相比差异无统计学意义。②骨密度T值≤-2.5[OR=1.822,95%CI(1.124,2.954),P=0.004]、血脂异常[OR=1.381,95%CI(1.038,1.836),P0.05]、TSH0.55 mIU/L[OR=2.469,95%CI(1.163,5.243),P0.05]是骨质疏松性骨折的危险因素,校正血脂异常、骨密度T值≤-2.5后,TSH降低组与TSH正常组相比,骨折风险增加2.626倍[OR=2.626,95%CI(1.233,5.592),P0.05]。结论绝经后女性TSH水平降低与骨质疏松性骨折风险增加相关。     

绝经后女性骨密度与腰椎间盘退变的相关性分析

目的:观察绝经后女性腰椎和髋部骨密度与腰椎间盘退变的关系。方法:回顾性统计2017年12月～2018年12月因腰痛在我院脊柱外科门诊及住院的229例绝经后女性患者,记录患者年龄、身高、体重、糖尿病史、高血压病史、饮酒史、吸烟史等,采用双能X线骨密度测量仪检查患者腰椎椎体(L1～L4)骨密度和髋部平均骨密度,记录相应的T值,每例患者同时行腰椎MRI检查。根据骨密度T值≥-1.0为正常,-2.5 T值-1.0为骨量减少,T值≤-2.5诊断为骨质疏松,将患者分为骨质疏松组(n=78)、骨量减少组(n=73)和正常组(n=78)。每个节段腰椎间盘退变程度用Pfirrmann分级系统进行评分,用协方差和Spearman相关性分析来分析腰椎和髋部骨密度与腰椎间盘退变的关系。结果:骨质疏松组、骨量减少组和骨量正常组的年龄分别为67.17±9.99岁、65.66±10.71岁、55.29±12.35岁,骨质疏松组、骨量减少组年龄显著大于骨量正常组(P0.05);骨质疏松组的体重指数小于正常组(23.38±2.37kg/m~2 vs 24.72±2.96kg/m~2,P0.05);其余一般资料各组间无显著性差异(P0.05)。上腰椎(L1、L2)中,骨质疏松组腰椎间盘退变评分均较正常组低(2.24±0.82 vs 2.60±0.95,2.79±0.95 vs3.18±0.94,P0.05),而与骨量减少组比较无显著性差异(P0.05);下腰椎(L3、L4)椎体和髋部不同骨密度组之间椎间盘退变程度无显著性差异(P0.05)。各腰椎椎体骨密度分别与腰椎间盘平均退变程度呈正性相关(L1:r=0.185;L2:r=0.157;L3:r=0.180;L4:r=0.132;L1～L4:r=0.180;均P0.05),髋部骨密度与腰椎间盘退变的严重程度无统计学相关性。结论:绝经后女性腰椎间盘退变的严重程度与腰椎骨密度存在正相关关系,提示绝经后女性腰椎骨密度较高者椎间盘退变可能更严重,有必要进一步做腰椎CT或者MRI检查;股骨颈骨密度检查对骨质疏松诊断更有帮助。     

50例绝经后高疾病活动期的女性类风湿关节炎骨密度的临床观察

目的观察绝经后高疾病活动期的女性类风湿关节炎患者骨矿物质密度水平的变化。方法收集50例绝经后女性RA患者一般临床资料,包括年龄、RA病程、绝经年龄、ESR、CRP、RF、抗CCP抗体、DSA28评分及雌二醇水平,应用双能X线吸收法(DXA)测定50例患者腰椎L_(1-4)和左髋关节部位的骨密度,分析其骨密度(BMD)的情况。结果 1.50例绝经后女性RA的DSA28评分大于5.1,属高疾病活动期,骨质疏松组发生率52%;远高于骨量减少组(30%)及骨密度正常组(18%)。2.骨质疏松组的绝经年龄比非骨质疏松组明显提前(P=0.005),抗CCP抗体水平明显升高(P=0.037),有统计学意义,但在年龄、病程、RF、DSA28评分及雌激素方面两者无统计学差异。3.Logistic回归分析结果显示抗CCP抗体(OR值1.025,P=0.041)是绝经后高疾病活动女性RA骨质疏松的独立危险因素。4.骨质疏松组,腰椎总骨密度较髋关节显著降低(P0.001);腰椎组内比较以腰1椎体BMD最低,而后依次为腰2,腰3、腰4(P=0.0003),左髋关节组内比较以大转子BMD最低,而后依次为股骨颈、小转子(P0.0001)。结论绝经后高疾病活动期的女性RA患者存在明显的骨质疏松,以腰椎骨密度(特别L_1)下降最明显;抗CCP抗体可能是高疾病活动期的女性类RA患者发生骨质疏松的危险因素。     

太极拳和快走练习对老年女性骨密度和骨代谢影响的跟踪研究

目的探索太极拳和快走锻炼对老年人骨密度和骨代谢的影响效果,为预防老年人骨质疏松提供数据支持。方法 60名老年女性被随机分成太极组、快走组和对照组。太极组和快走组分别接受16周的太极拳锻炼和快走锻炼,每周5次,每次1小时,随后停止练习跟踪8周。受试者每4周测试一次骨密度和骨代谢,共测试7次(锻炼前、锻炼后的第4、8、12、16周,停止锻炼后的第4、8周)。结果锻炼阶段,快走组的骨质指数(bone quality index,BQI)、宽带超声衰减(broadband ultrasound attenuation,BUA)、超声速度(speed of sound,SOS)、血清钙(Ca)、血清磷(P)和碱性磷酸酶(alkaline phosphate,ALP)指标在第12周出现显著性改善;太极组指标在第16周出现显著性改善或者趋势。停练阶段,快走组和太极组各指标未出现显著性衰退,但第20周BUA和SOS指标两组组间差异出现显著性。结论锻炼阶段,太极拳和快走运动均能改善老年女性的骨密度和骨代谢;在停练阶段,快走对骨密度和骨代谢的维持效果要好于太极拳锻炼。因此,相比于太极拳锻炼,老年人可以考虑将快走运动作为首选的改善骨密度的锻炼方式,以预防骨质疏松。     

影响维持性血液透析患者骨密度相关因素分析

目的观察维持性血液透析患者骨质疏松现状,研究骨密度及骨代谢指标间关系,讨论影响骨质疏松的危险因素。方法选取维持性血液透析患者125例,收集一般资料及透析相关信息,检测25羟维生素D,骨源性碱性磷酸酶,跟骨骨密度,进行横断面研究。应用SPSS19.0软件,P0.05为差异有统计学意义。结果维持性血液透析患者骨质疏松发生率为48%,25羟维生素D缺乏为30.4%。不同性别间骨质疏松患病率差异无统计学意义。绝经女性骨密度显著低于未绝经女性(P0.001)。女性25羟维生素D水平显著低于男性(P=0.026)。肾小管间质性疾病者骨密度明显低于慢性肾小球肾炎者(P=0.001)。不运动者骨密度明显低于运动者(P0.001)。骨密度与年龄,透析龄显著负相关(r=-0.387,P0.001,r=-0.190 P=0.034)。老龄、绝经、轻体重、不运动、肾移植是维持性透析患者骨质疏松的危险因素。结论维持性血液透析患者骨质疏松和25羟维生素D缺乏发生率高,但二者间无相关性。老龄、绝经、轻体重、不运动、肾移植后应用激素及免疫抑制剂是终末期肾病维持性透析患者骨质疏松的危险因素。     

血清维生素K1水平与绝经后女性腰椎骨密度相关性分析

目的探讨绝经后女性骨密度与血清维生素K1水平之间的相关性。方法使用标准化的酶联免疫吸附试验(ELISA)试剂盒测量46例绝经后骨质疏松女性和30名绝经后健康对照女性的血清维生素K1水平。检测腰椎(1～4)的骨密度(bone mineral density, BMD)。结果绝经后骨质疏松女性组血清维生素K1水平明显低于正常对照组(P0.05),绝经后骨质疏松女性血清维生素K1浓度与腰椎BMD呈正相关(R=0.545,P=0.003);绝经后正常对照组血清维生素K1浓度与腰椎BMD呈正相关(R=0.513,P=0.009)。维生素K1对骨质疏松症的诊断敏感性和特异性分别为91%和98%(截止值:0.853 ng/mL);维生素K1的ROC曲线下面积(AUC)为0.985,奇数比为18.88。结论维生素K1与诊断绝经后骨质疏松症呈负相关。     

Changes in QUS and BMD Measurements with Antiresorptive Therapy: A Two-Year Longitudinal Study

There is lack of consensus on whether quantitative ultrasound (QUS) measurements can be used to monitor response to therapy. The aim of this 2-year longitudinal study was to assess whether calcaneal QUS measurement variables respond to antiresorptive therapy and whether these measurements display adequate long-term precision to be useful for monitoring purposes. The study population consisted of 195 postmenopausal women divided into three groups: Group 1: 39 women treated with antiresorptive therapy who commenced treatment at baseline; Group 2: 25 women treated with antiresorptive therapy who had been on treatment for at least 2 years at baseline; Group 3: 131 women who did not taken estrogen, bisphosphonates, or calcium during the 2-year study period. Subjects had baseline and 12 and 24 months follow-up BMD measurements at the lumbar spine (LS), femoral neck (FN), and total hip (THIP) and calcaneal QUS measurements of broadband ultrasound attenuation (BUA) and speed of sound (SOS). BUA and SOS were combined to provide an estimate of heel BMD (Est heel BMD). For women in Group 1, all BMD and QUS measurement variables increased significantly from baseline after 2 years of treatment. For women in Group 2, only THIP BMD and BUA increased significantly after 2 years and the changes were less than those observed in Group 1 women. The overall treatment effect for each measurement variable, defined as the difference in the mean absolute changes between Groups I and 3 after 2 years, was 0.08, 0.03, and 0.04 g/cm2 for LS, FN, and THIP BMD, and for BUA, SOS, and Est heel BMD it was 5.8 dB/MHz, 13.1 m/sec, and 0.05 g/cm2, respectively. When the overall treatment effect was expressed in T-score units, the effect was greatest for LS BMD (0.65 T-score units) and lowest for FN BMD (0.31 T-score units). QUS measurement variables yielded intermediate values of 0.43- 0.52 T-score units. The average least significant change (LSC) was 0.38 T-score units for BMD measurements, whereas the LSC for QUS measurements was three times greater at approximately 1.20 T-score units. Ninety-four percent of the women in Group 1 showed changes in LS BMD that exceeded the LSC after two years, while the percentage was lower for the other measurement variables ranging from approximately 6% for FN BMD, SOS and Est heel BMD to 50% for THIP BMD. A lower percentage of women in Groups 2 and 3 displayed changes that exceeded the LSC for both BMD and QUS measurement variables. Changes in all QUS variables were significantly correlated with changes in LS BMD, with correlation coefficients ranging from 0.26 to 0.40. In conclusion, calcaneal QUS measurement variables were found to show a highly significant response to antiresorptive therapy. However, the precision of QUS measurements was not good enough to allow QUS to be used for monitoring response to treatment. Future improvements in the precision of calcaneal QUS measurements are required to increase the utility of QUS for monitoring purposes.     

Screening with ultrasound of the heel may contribute to the prevention in osteoporosis

<正> Objective:To calibrate a Quantitative Ultrasonography(QUS)system against densitometryby defining the sensitivity and specificity of the method,and to propose a series of QUS interpre-tation thresholds to classify the individual risk with regards to the risk of developing osteoporosisin later life.Methods:Subjects were recruited in New York City over a 1-year period.Women with amen-orrhea for at least 12 months were defined as postmenopausal,and all other women as premeno-pausal.Bone mineral density(BMD)was measured with a dual energy X-ray absorptiometer(DXA)and QUS performed with the calcaneus of broadband ultrasound attenuation(BUA)andspeed of sound(SOS)using the Lunar Achilles system.Statistical analysis was performed usingSPSS software Version 10.0.Results:Two hundred twenty-eight premenopausal and menopausal women were recruited.Most of the participants were Hispanic,Caucasian and African-American in this study.All thesubjects had DXA and QUS examined and T-score was got from both.The statistical resultsshowed that the T-score of QUS has a significant relationship with that of DXA(spine:r=0.557,P<0.0001;femur:r=0.611,P<0.0001).Both QUS and DXA T-score has a significant andnegative relationship with age(QUS:r=-0.241,P<0.0001;Spine:r=-0.277,P<0.0001;femur:-0.296,P<0.0001).When T-score of heel ultrasound -1.5 was set as the interpreta-tion threshold,the osteoporosis patients with T-score of DXA-femur scan(100%)and DXA-spine(77.10%)less than -2.5 were detected.As well,the specificities of T-score -1.5 ofQUS for DXA-femur and DXA-spine were 67.5% and 72.8%,respectively.In addition,if we set-1.0 of T-score of QUS as the cutoff,74.80% and 79.60% of the osteopenia based on DXA ofspine and femur were identified.The specificities were 59.4% and 57.7%.Conclusions:QUS of the calcaneus may be an effective method for providing risk stratifica-tion for osteoporosis,and for the closely associated future risk for fragility-fracture.     

Imaging Ultrasonometry of the Calcaneus: Optimum T-Score Thresholds for the Identification of Osteoporotic Subjects

The purpose of the present study was to (1) examine the age dependence of T-score results for calcaneal imaging ultrasonometry and dual X-ray absorptiometry of the axial skeleton and (2) determine the optimum T-score thresholds appropriate for broadband ultrasound attenuation (BUA) and speed of sound (SOS) measurements. A total of 453 healthy women aged 20-9 years were included in the study. All study participants underwent bone mineral density (BMD) measurements of the lumbar spine, femoral neck, total hip and calcaneal measurements of the BUA and SOS. An imaging ultrasound device (UBIS, DMS, France) was used for the ultrasound measurements. T-scores were calculated using a subgroup of 71 healthy women aged 20-35 years to estimate the mean value of young normals and SD for BUA, SOS, and BMD. The age-related decline in both BUA and SOS T-scores was slower than that in the equivalent figures obtained by BMD measurements. The optimum T-score thresholds estimated by receiver operating characteristic (ROC) analysis were 1.3 for BUA and 1.5 for SOS. Using the optimum threshold, the sensitivity and specificity for BUA was 68% and 83%, respectively. Corresponding values for SOS were 63% and 79%. Utilizing calculated optimum T score thresholds for BUA and SOS, the agreement among BUA, SOS, and BMD at the femoral neck was improved compared with that found using the T-score of < or = -2.5 criterion. In conclusion, the definition of osteoporosis by a T-score of , or = -2.5 was not applicable to imaging ultrasonometry of the calcaneus. Optimum T-score thresholds were determined for both BUA and SOS suitable to Ubis QUS device.     

辛伐他汀对绝经伴血脂代谢异常女性跟骨骨密度的影响

目的 研究辛伐他汀对绝经后伴血脂代谢异常女性跟骨骨密度的影响。方法 分析885名绝经后口服辛伐他汀治疗血脂代谢异常（TC>5.18mmol/L 或 LDL-C> 3.37mmol/L）女性的跟骨骨密度,并依据T值分为骨质正常、骨量减少、骨质疏松。结果 治疗前跟骨骨密度为305.3± 59.2 mg/cm2,骨质正常、骨量减少、骨质疏松的人数分别为115、446、324,口服辛伐他汀（20mg/d）治疗3月后骨密度为309.7±56.3 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为117、459、319,12月后跟骨骨密度为312.5±60.9 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为122、460、303。结论 绝经后伴血脂代谢异常女性应用辛伐他汀（20mg/d）治疗12个月后跟骨骨密度增高,但对骨质疏松患病风险无影响。     

Use of a Swedish T-score reference population for women causes a two-fold increase in the amount of postmenopausal Swedish patients that fulfill the WHO criteria for osteoporosis

The WHO criteria for osteoporosis are based on bone mineral density (BMD) values in comparison to a reference population of healthy young adults. The aim of this study was to create BMD references for ethnic Swedish women, and to investigate whether the use of these T-score measurements influence the amount of Swedish postmenopausal patients that are diagnosed as having osteoporosis. A bone density reference was created by measuring a population-based sample of 335 randomly selected Swedish women aged 20-39yr. BMD was measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine, proximal femur, and total body. These locally derived T-score values were subsequently used to diagnose a sample of 300 consecutive postmenopausal Swedish patients referred to the Uppsala Osteoporosis Unit. There was a slight age-dependent decrease in femoral neck BMD, whereas no age effect was seen at other sites such as total hip, lumbar spine, or total body. This suggests that the cohort represents the steady state BMD at the ages of expected peak bone mass in Swedish women. The correlation between BMD measures at different sites differed from r=0.55 (lumbar spine BMD vs femoral neck BMD [FNBMD]) to r=0.92 (total hip BMD vs FNBMD). Central DXA-generated T-scores were calculated from this cohort, and these were significantly higher (0.3-0.5 SD) as compared with manufacturers and NHANESIII reference populations. This indicates that young Swedish women have a higher peak bone mass than the subjects included in the reference populations currently used for clinical measurements. The T-score in total hip derived from the investigated cohort was subsequently used to diagnose 300 clinical patients (mean age 63yr) referred for a DXA scan by their physicians. The use of this locally established and ethnic representative, T-score reference increased the prevalence of osteoporosis in femoral neck and total hip with 53-106%. A Swedish female BMD reference representing peak bone mass has been established and the normative data are presented. Notably, this cohort has considerably higher BMD as compared to the NHANESIII and manufacturer's reference populations. The use of the present T-score reference therefore causes approximately a 2-fold increase in the amount of Swedish postmenopausal women that fulfill the WHO criteria for osteoporosis. This demonstrates the problems with using T-score as diagnostic threshold for osteoporosis and is an argument for future strategies to obtain standardized densitometric cut-offs, for example, mg/cm(2).     

Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis

The purpose of this prospective study was to determine whether moderate walking exercise in postmenopausal women with osteopenia/osteoporosis would affect bone metabolism. Fifty postmenopausal women, aged 49–75 years, with osteopenia/osteoporosis were recruited: 32 women entered the exercise program (the exercise group) and 18 served as controls (the control group). The exercise consisted of daily outdoor walking, the intensity of which was 50% of maximum oxygen consumption, with a duration of at least 1h with more than 8000 steps, at a frequency of 4 days a week, over a 12-month period. Lumbar (L2–L4) bone mineral density (BMD) was measured at the baseline and every 6 months with dual-energy X-ray absorptiometry (DXA) in both groups. Serum bone-specific alkaline phosphatase (BAP) and urinary cross-linked N-terminal telopeptides of type I collagen (NTX) levels were measured at baseline and at months 1, 3, 6, 9, and 12 by EIA and ELISA, respectively, in the exercise group, and urinary NTX level was measured at the baseline and every 6 months in the control group. There were no significant differences in baseline characteristics including age, height, body weight, bone mass index, years since menopause, lumbar BMD, and urinary NTX level between the two groups. Although no significant changes were observed in lumbar BMD and the urinary NTX level in the control group, lumbar BMD in the exercise group was increased as compared with the control group, but was sustained from the baseline. In the exercise group, the urinary NTX level rapidly responded to walking exercise from month 3, and this reduction was sustained until month 12, followed by reduction in the serum BAP level. A moderately negative correlation was found between the percent change in the urinary NTX level at month 3 and that in lumbar BMD at month 12 in the exercise group. This study clearly demonstrates that the mechanism for the positive response of lumbar BMD to moderate walking exercise in postmenopausal women with osteopenia/osteoporosis appears to be the suppression of bone turnover, and that an early change in the urinary NTX level may be useful to predict the long-term response of increasing lumbar BMD to exercise, although its efficacy for lumbar BMD may be quite modest.     

Commencing, Continuing and Stopping Brisk Walking: Effects on Bone Mineral Density, Quantitative Ultrasound of Bone and Markers of Bone Metabolism in Postmenopausal Women

Regular walking is associated with reduced risk of fracture and, in our recent randomized trial, reduced calcaneal bone loss relative to controls. The present follow-up study compared the effects on dual-energy X-ray absorptiometry, ultrasound and biochemical indices of bone density and metabolism of (i) taking up (ii) continuing with and (iii) ceasing brisk walking for exercise. Subjects were 68 postmenopausal women aged 60–70 years. Twenty previously sedentary women remained sedentary (Sed/Sed) whilst 17 took up brisk walking (Sed/Walk). Fifteen women who had been walking regularly for 1 year returned to their former sedentary lifestyle (Walk/Sed), whilst 16 continued brisk walking over a second year (Walk/Walk). Bone mineral density (BMD), broadband ultrasonic attenuation (BUA), and biochemical markers of bone formation (serum osteocalcin, C-terminal propeptide of type I collagen and bone alkaline phosphatase) and resorption (urinary deoxypyridinoline) were assessed at baseline and 12 months. Women in the Sed/Walk and Walk/Walk groups completed a mean (SEM) of 16.9 (0.7) and 20.8 (1.2) min of brisk walking per day, respectively. Changes in BMD did not differ significantly between groups. Calcaneal BMD decreased significantly in Walk/Sed women [by 2.7 (1.4)%; p= 0.01] whilst changes in other groups were not significant. Calcaneal BUA increased significantly (p= 0.02) in Sed/Walk women [by 7.4 (3.3)%] relative to other groups. Urinary deoxypyridinoline increased over the year in the Sed/Sed group but there were no significant changes in biochemical markers in other groups. Women taking up brisk walking for exercise showed no change in BMD but a significant increase in calcaneal BUA. There was no significant effect on BMD or BUA of continuing brisk walking but calcaneal BMD declined on ceasing brisk walking. Bone resorption increased in sedentary women but not exercisers, suggesting the effect on exercise on bone in postmenopausal women could be through amelioration of this increased turnover. Received: 12 September 2000 / Accepted: 13 February 2001     

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

This study evaluated the efficacy and tolerability of risedronate once a week (35 mg and 50 mg) compared with risedronate 5 mg once daily in women with osteoporosis. We conducted a randomized, double-blind, active-controlled, 2-year study; the primary efficacy assessment was performed after 1 year. Subjects were women aged 50 years or older who had been postmenopausal for at least 5 years, with either a bone mineral density (BMD) T-score of -2.5 or lower (lumbar spine or proximal femur) or a T-score lower than -2 and at least one prevalent vertebral fracture. Subjects received risedronate 5 mg once daily, 35 mg once a week or 50 mg once a week. All subjects also received 1 g daily of elemental calcium supplementation and supplemental vitamin D if the baseline serum levels were low. The primary efficacy measure was percent change in lumbar spine BMD at 12 months. A total of 1,456 women were randomized and received medication; 1,209 (83%) women completed 12 months. The mean percent change (SE) in lumbar spine BMD after 12 months was 4.0% (0.2%) in the 5 mg daily group, 3.9% (0.2%) in the 35 mg group, and 4.2% (0.2%) in the 50 mg group; each once-a-week treatment was determined to be as effective as the daily treatment. Outcomes of the secondary efficacy measurements and safety assessments were also similar in all 3 groups after 12 months. Risedronate 35 mg and 50 mg once a week provide the same efficacy and safety as the daily 5 mg regimen; therefore, the lower dose, 35 mg once a week, is considered optimal for women with postmenopausal osteoporosis who desire a once-a-week regimen.     

鲑鱼降钙素治疗维持性血液透析骨量减少的患者

目的 观察长期应用鲑鱼降钙素对维持性血液透析（MHD）骨量减少患者的骨矿密度（BMD）、骨代谢生化指标及骨痛的作用。 方法 选择经双能X线诊断为骨量减少的MHD患者34例，给予鲑鱼降钙素皮下注射50 U/次，每周3次，连续12个月。比较治疗前后腰椎、髋部骨密度参数、血清骨代谢生化指标以及主观骨痛评分。同时观察该药的不良反应。结果 共有32例患者完成随访。与治疗前比较，治疗后第2腰椎Z值（-0.44±1.82 比0.06±1.63，P = 0.016）、腰椎总体Z值（-0.90±2.15比0.08±2.05，P = 0.002）、第3腰椎T值（-2.02±2.51比1.24±2.02，P = 0.033）、腰椎总体T值（-1.98±2.20比1.26±1.88，P = 0.009）、股骨大转子Z值（-0.65±1.11比0.48±1.12，P = 0.034）、粗隆间Z值（-0.58±0.94比0.02±1.12，P = 0.006）、髋部总体Z值（-0.66±0.80比0.08±1.08，P = 0.029）及髋部总体T值（-1.72±1.53比1.06±1.58，P = 0.016）显著增加，差异均有统计学意义。各项血清骨代谢生化指标治疗前后差异均无统计学意义。治疗1个月骨痛主观评分下降41.7%（P < 0.01）；6个月下降76.6%（P < 0.01）；12个月时保持6个月时的水平。该药的不良反应主要为恶心呕吐5例（14.71%，5/34），头晕、颜面潮红、心慌各1例（3.13%，1/32）。 结论 骨量减少的MHD患者长期皮下注射鲑鱼降钙素可改善BMD；有效缓解骨痛；但对血清骨代谢相关生化指标无明显影响。MHD患者长期应用鲑鱼降钙素是安全的，恶心呕吐较常见。     

Measurements of broadband ultrasonic attenuation in the calcaneus in premenopausal and postmenopausal women

We report a study of broadband ultrasonic attenuation (BUA) in the calcaneus in 248 women. Measurements were performed with a Walker-Sonix UBA-575 ultrasonic bone analyser. The populations studied were 15 healthy young volunteers (group 1, mean age 26 years), 200 healthy pre- and postmenopausal women (group 2, mean age 53 years) and 33 osteoporotic women with vertebral crush fractures (group 3, mean age 66 years). Subjects in group 1 each had 10 repeated measurements of their right heel. Duplicate BUA measurements in the right heel were performed in 96 subjects and bilateral scans in a further 87 women in group 2. The remaining 17 subjects in group 2 and those in group 3 had a single scan of the right heel. All women in groups 2 and 3 had dual X-ray absorptiometry (DXA) scans of the lumbar spine and femoral neck.The precision study on the women in group 1 gave a root mean square (RMS) coefficient of variation (CV) of 4.2%. Individual CV results showed statistically significant differences (range 1.3%–7.6%). Duplicate scans in subjects in group 2 gave a RMS CV of 4.6% while the bilateral measurements showed no significant difference between the two heels. Linear regression analysis gave the following relationship between BUA and age: BUA=87.1–0.76 (Age –40) dB/MHz (r=–0.31,p<0.001, SEE=14.0 dB/MHz). Multivariate regression analysis showed that, in addition to age, years since the menopause was also a significant factor in predicting BUA. In the first 5 years following the menopause BUA decreased by 2.5%/year, while in the next 5 years the decrease fell to 0.5%/year. The BUA measurements in the osteoporotic subjects in group 3 gave a mean T-score of –2.1 compared with 66 premenopausal normal women and a mean Z-score of –1.0 compared with 27 age-matched elderly normal women in group 2. In comparison the lumbar spine DXA measurements for the same women gave a mean T-score of –3.2 and a mean Z-score of –1.8. DXA therefore gave substantially better discrimination between osteoporotic and normal subjects than the BUA measurements.